{"id":"opc-12759","safety":{"commonSideEffects":[{"rate":"null","effect":"Orthostatic hypotension"},{"rate":"null","effect":"Somnolence"},{"rate":"null","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by blocking the action of dopamine at D2 receptors in the brain, which is thought to be involved in the pathophysiology of schizophrenia. This blockade is believed to help alleviate symptoms of psychosis and negative symptoms associated with schizophrenia.","oneSentence":"OPC-12759 is a selective dopamine D2 receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:24.174Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of schizophrenia"}]},"trialDetails":[{"nctId":"NCT01471093","phase":"PHASE1","title":"Safety Study of OPC-12759 Ophthalmic Solution","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2011-11","conditions":"Dry Eye Syndromes","enrollment":100},{"nctId":"NCT01660256","phase":"PHASE3","title":"Confirmatory Study of OPC-12759 Ophthalmic Solution","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2012-08","conditions":"Dry Eye","enrollment":209},{"nctId":"NCT03608761","phase":"PHASE4","title":"Comparison Between Rebamipide 2% Versus Autologous Serum","status":"COMPLETED","sponsor":"Hospital Nacional Profesor Alejandro Posadas","startDate":"2017-02-06","conditions":"Dry Eye Syndromes, Sjögren Syndrome","enrollment":21},{"nctId":"NCT01493180","phase":"PHASE2","title":"Exploratory Study of OPC-12759 Ophthalmic Suspension","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2011-12","conditions":"Keratoconjunctival Epithelial Disorder","enrollment":102},{"nctId":"NCT00234078","phase":"PHASE2","title":"Dose-response Study of OPC-12759 Ophthalmic Suspension","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2005-01","conditions":"Dry Eye Syndromes","enrollment":290},{"nctId":"NCT00818324","phase":"PHASE3","title":"Long Term Administration Study of OPC-12759 Ophthalmic Suspension","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2009-01","conditions":"Dry Eye Syndromes","enrollment":154},{"nctId":"NCT00885079","phase":"PHASE3","title":"Confirmatory Study of OPC-12759 Ophthalmic Suspension","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2009-05","conditions":"Dry Eye Syndromes","enrollment":188},{"nctId":"NCT00475319","phase":"PHASE2","title":"Late Phase 2 Study of OPC-12759 Ophthalmic Suspension","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2007-05","conditions":"Dry Eye Syndromes","enrollment":308},{"nctId":"NCT01057147","phase":"PHASE2","title":"Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea","status":"COMPLETED","sponsor":"Kubota Vision Inc.","startDate":"2010-02","conditions":"Keratoconjunctivitis Sicca, Dry Eye","enrollment":116},{"nctId":"NCT01027013","phase":"PHASE2","title":"Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye","status":"COMPLETED","sponsor":"Kubota Vision Inc.","startDate":"2009-12","conditions":"Dry Eye Syndromes, Keratoconjunctivitis Sicca","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rebamipide"],"phase":"phase_3","status":"active","brandName":"OPC-12759","genericName":"OPC-12759","companyName":"Otsuka Pharmaceutical Co., Ltd.","companyId":"otsuka-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OPC-12759 is a selective dopamine D2 receptor antagonist. Used for Treatment of schizophrenia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}